EGFR and non-small cell lung carcinoma: In this study, we demonstrate that NSCLC patients with EGFR mutations had lower pSUVmax measurements based on 18F–FDG PET than NSCLC patients with wild-type EGFR and that low pSUVmax could be integrated with other clinical factors to enhance the discriminability on the EGFR mutation status in some NSCLC patients whose EGFR testing is unavailable.